Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

In 17 EGFR wild-type non-small cell lung cancer patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7...

Related Keywords

Seoul ,Soult Ukpyolsi ,South Korea ,Ukraine ,Germany ,Texas ,United States ,Mannheim ,Baden Wüberg ,Artiva Allo ,Alexander Fudukidis ,Mary Beth Sandin ,Andreas Harstrick ,Hye Ryun Kim ,Yonsei University College Of Medicine ,University Of Texas Md Anderson Cancer Center ,Globenewswire Inc ,Chief Medical ,Chief Executive Officer ,Gryun Kim ,University College ,Cancer Center ,